{
  "DOI": "10.1186/s40246-023-00461-z",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-023-00461-z",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eGenetic variability in the cytochrome P450 CYP2C9 constitutes an important predictor for efficacy and safety of various commonly prescribed drugs, including coumarin anticoagulants, phenytoin and multiple non-steroidal anti-inflammatory drugs (NSAIDs). A global map of \u003cjats:italic\u003eCYP2C9\u003c/jats:italic\u003e variability and its inferred functional consequences has been lacking.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eFrequencies of eight functionally relevant \u003cjats:italic\u003eCYP2C9\u003c/jats:italic\u003e alleles (\u003cjats:italic\u003e*2\u003c/jats:italic\u003e, \u003cjats:italic\u003e*3\u003c/jats:italic\u003e, \u003cjats:italic\u003e*5\u003c/jats:italic\u003e, \u003cjats:italic\u003e*6\u003c/jats:italic\u003e, \u003cjats:italic\u003e*8\u003c/jats:italic\u003e, \u003cjats:italic\u003e*11\u003c/jats:italic\u003e, \u003cjats:italic\u003e*13\u003c/jats:italic\u003e and \u003cjats:italic\u003e*14\u003c/jats:italic\u003e) were analyzed. In total, 108 original articles were identified that included genotype data from a total of 81,662 unrelated individuals across 70 countries and 40 unique ethnic groups. The results revealed that \u003cjats:italic\u003eCYP2C9*2\u003c/jats:italic\u003e was most abundant in Europe and the Middle East, whereas \u003cjats:italic\u003eCYP2C9*3\u003c/jats:italic\u003e was the main reason for reduced CYP2C9 activity across South Asia. Our data show extensive variation within superpopulations with up to tenfold differences between geographically adjacent populations in Malaysia, Thailand and Vietnam. Translation of genetic \u003cjats:italic\u003eCYP2C9\u003c/jats:italic\u003e variability into functional consequences indicates that up to 40% of patients in Southern Europe and the Middle East might benefit from warfarin and phenytoin dose reductions, while 3% of patients in Southern Europe and Israel are recommended to reduce starting doses of NSAIDs.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusions\u003c/jats:title\u003e\n                \u003cjats:p\u003eThis study provides a comprehensive map of the genetic and functional variability of CYP2C9 with high ethnogeographic resolution. The presented data can serve as a useful resource for \u003cjats:italic\u003eCYP2C9\u003c/jats:italic\u003e allele and phenotype frequencies and might guide the optimization of genotyping strategies, particularly for indigenous and founder populations with distinct genetic profiles.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "461"
  ],
  "article-number": "15",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "4 November 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "16 February 2023"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "28 February 2023"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "YZ and VML are co-founders and shareholders of PersoMedix AB. In addition, VML is CEO and shareholder of HepaPredict AB. EE is vice-chair of the Genomic Medicine Sweden Pharmacogenomics work package, supported by grants from The Swedish Innovation Agency. EE also received funding from the Stockholm Region (CIMED). The other authors do not disclose competing interests."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Zhou",
      "given": "Yitian",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Nevosadová",
      "given": "Lenka",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Eliasson",
      "given": "Erik",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Lauschke",
      "given": "Volker M.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        2,
        28
      ]
    ],
    "date-time": "2023-02-28T14:02:52Z",
    "timestamp": 1677592972000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        2,
        28
      ]
    ],
    "date-time": "2023-02-28T15:11:36Z",
    "timestamp": 1677597096000
  },
  "funder": [
    {
      "DOI": "10.13039/501100004047",
      "doi-asserted-by": "crossref",
      "name": "Karolinska Institute"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        20
      ]
    ],
    "date-time": "2024-03-20T16:52:52Z",
    "timestamp": 1710953572306
  },
  "is-referenced-by-count": 11,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2023,
        2,
        28
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2023,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            2,
            28
          ]
        ],
        "date-time": "2023-02-28T00:00:00Z",
        "timestamp": 1677542400000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            2,
            28
          ]
        ],
        "date-time": "2023-02-28T00:00:00Z",
        "timestamp": 1677542400000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00461-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-023-00461-z/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-023-00461-z.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2023,
        2,
        28
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        2,
        28
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1136/bmj.329.7456.15",
      "author": "M Pirmohamed",
      "doi-asserted-by": "publisher",
      "first-page": "15",
      "issue": "7456",
      "journal-title": "BMJ",
      "key": "461_CR1",
      "unstructured": "Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.",
      "volume": "329",
      "year": "2004"
    },
    {
      "DOI": "10.1046/j.0306-5251.2001.01407.x",
      "author": "P Impicciatore",
      "doi-asserted-by": "publisher",
      "first-page": "77",
      "issue": "1",
      "journal-title": "Br J Clin Pharmacol",
      "key": "461_CR2",
      "unstructured": "Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52(1):77–83.",
      "volume": "52",
      "year": "2001"
    },
    {
      "DOI": "10.1371/journal.pone.0252161",
      "author": "WN Insani",
      "doi-asserted-by": "publisher",
      "first-page": "e0252161",
      "issue": "5",
      "journal-title": "PLoS ONE",
      "key": "461_CR3",
      "unstructured": "Insani WN, Whittlesea C, Alwafi H, Man KKC, Chapman S, Wei L. Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis. PLoS ONE. 2021;16(5):e0252161.",
      "volume": "16",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.ejps.2019.01.024",
      "author": "VM Lauschke",
      "doi-asserted-by": "publisher",
      "first-page": "65",
      "journal-title": "Eur J Pharm Sci",
      "key": "461_CR4",
      "unstructured": "Lauschke VM, Ingelman-Sundberg M. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. Eur J Pharm Sci. 2019;130:65–77.",
      "volume": "130",
      "year": "2019"
    },
    {
      "DOI": "10.1016/j.pharmthera.2012.12.007",
      "author": "UM Zanger",
      "doi-asserted-by": "publisher",
      "first-page": "103",
      "issue": "1",
      "journal-title": "Pharmacol Ther",
      "key": "461_CR5",
      "unstructured": "Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.",
      "volume": "138",
      "year": "2013"
    },
    {
      "DOI": "10.1124/jpet.116.233635",
      "author": "HF Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "83",
      "issue": "1",
      "journal-title": "J Pharmacol Exp Ther",
      "key": "461_CR6",
      "unstructured": "Zhang HF, Wang HH, Gao N, Wei JY, Tian X, Zhao Y, et al. Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human normal liver microsomes. J Pharmacol Exp Ther. 2016;358(1):83–93.",
      "volume": "358",
      "year": "2016"
    },
    {
      "DOI": "10.3390/jpm8010001",
      "author": "AK Daly",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "J Pers Med",
      "key": "461_CR7",
      "unstructured": "Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017;8(1):1.",
      "volume": "8",
      "year": "2017"
    },
    {
      "DOI": "10.1097/00008571-200312000-00002",
      "author": "U Yasar",
      "doi-asserted-by": "publisher",
      "first-page": "715",
      "issue": "12",
      "journal-title": "Pharmacogenetics",
      "key": "461_CR8",
      "unstructured": "Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics. 2003;13(12):715–20.",
      "volume": "13",
      "year": "2003"
    },
    {
      "DOI": "10.1016/S0920-1211(99)00017-0",
      "author": "AE Rettie",
      "doi-asserted-by": "publisher",
      "first-page": "253",
      "issue": "3",
      "journal-title": "Epilepsy Res",
      "key": "461_CR9",
      "unstructured": "Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999;35(3):253–5.",
      "volume": "35",
      "year": "1999"
    },
    {
      "DOI": "10.1038/tpj.2013.22",
      "author": "Y Niinuma",
      "doi-asserted-by": "publisher",
      "first-page": "107",
      "issue": "2",
      "journal-title": "Pharmacogenomics J",
      "key": "461_CR10",
      "unstructured": "Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 2014;14(2):107–14.",
      "volume": "14",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.clpt.2004.08.009",
      "author": "J Kirchheiner",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR11",
      "unstructured": "Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1–16.",
      "volume": "77",
      "year": "2005"
    },
    {
      "DOI": "10.1038/clpt.2014.159",
      "author": "KE Caudle",
      "doi-asserted-by": "publisher",
      "first-page": "542",
      "issue": "5",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR12",
      "unstructured": "Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014;96(5):542–8.",
      "volume": "96",
      "year": "2014"
    },
    {
      "DOI": "10.1097/FPC.0b013e3283349e84",
      "author": "D Van Booven",
      "doi-asserted-by": "publisher",
      "first-page": "277",
      "issue": "4",
      "journal-title": "Pharmacogenet Genomics",
      "key": "461_CR13",
      "unstructured": "Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20(4):277–81.",
      "volume": "20",
      "year": "2010"
    },
    {
      "DOI": "10.1097/FPC.0b013e32831ebb30",
      "author": "J Sistonen",
      "doi-asserted-by": "publisher",
      "first-page": "170",
      "issue": "2",
      "journal-title": "Pharmacogenet Genomics",
      "key": "461_CR14",
      "unstructured": "Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009;19(2):170–9.",
      "volume": "19",
      "year": "2009"
    },
    {
      "DOI": "10.1517/17425255.2015.1111871",
      "author": "C Céspedes-Garro",
      "doi-asserted-by": "publisher",
      "first-page": "1893",
      "issue": "12",
      "journal-title": "Expert Opin Drug Metab Toxicol",
      "key": "461_CR15",
      "unstructured": "Céspedes-Garro C, Fricke-Galindo I, Naranjo ME, Rodrigues-Soares F, Fariñas H, de Andrés F, et al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin Drug Metab Toxicol. 2015;11(12):1893–905.",
      "volume": "11",
      "year": "2015"
    },
    {
      "DOI": "10.1002/cpt.2333",
      "author": "K Sangkuhl",
      "doi-asserted-by": "publisher",
      "first-page": "662",
      "issue": "3",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR16",
      "unstructured": "Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, et al. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021;110(3):662–76.",
      "volume": "110",
      "year": "2021"
    },
    {
      "author": "S Nizamuddin",
      "first-page": "135",
      "journal-title": "Pharmgenomics Pers Med",
      "key": "461_CR17",
      "unstructured": "Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K. CYP2C9 variations and their pharmacogenetic implications among diverse South Asian populations. Pharmgenomics Pers Med. 2021;14:135–47.",
      "volume": "14",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41397-022-00288-2",
      "doi-asserted-by": "crossref",
      "key": "461_CR18",
      "unstructured": "Zhou Y, Lauschke VM. The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data. Pharmacogenomics J. 2022."
    },
    {
      "DOI": "10.1038/ncomms3543",
      "author": "MD Costa",
      "doi-asserted-by": "publisher",
      "first-page": "2543",
      "journal-title": "Nat Commun",
      "key": "461_CR19",
      "unstructured": "Costa MD, Pereira JB, Pala M, Fernandes V, Olivieri A, Achilli A, et al. A substantial prehistoric European ancestry amongst Ashkenazi maternal lineages. Nat Commun. 2013;4:2543.",
      "volume": "4",
      "year": "2013"
    },
    {
      "DOI": "10.1093/molbev/msl124",
      "author": "C Hill",
      "doi-asserted-by": "publisher",
      "first-page": "2480",
      "issue": "12",
      "journal-title": "Mol Biol Evol",
      "key": "461_CR20",
      "unstructured": "Hill C, Soares P, Mormina M, Macaulay V, Meehan W, Blackburn J, et al. Phylogeography and ethnogenesis of aboriginal Southeast Asians. Mol Biol Evol. 2006;23(12):2480–91.",
      "volume": "23",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.ajhg.2008.08.001",
      "author": "S Xu",
      "doi-asserted-by": "publisher",
      "first-page": "322",
      "issue": "3",
      "journal-title": "Am J Hum Genet",
      "key": "461_CR21",
      "unstructured": "Xu S, Jin L. A genome-wide analysis of admixture in Uyghurs and a high-density admixture map for disease-gene discovery. Am J Hum Genet. 2008;83(3):322–36.",
      "volume": "83",
      "year": "2008"
    },
    {
      "DOI": "10.1073/pnas.0903045106",
      "author": "I Silva-Zolezzi",
      "doi-asserted-by": "publisher",
      "first-page": "8611",
      "issue": "21",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "461_CR22",
      "unstructured": "Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J, Fernandez-Lopez JC, Uribe-Figueroa L, Contreras A, et al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc Natl Acad Sci USA. 2009;106(21):8611–6.",
      "volume": "106",
      "year": "2009"
    },
    {
      "DOI": "10.1089/gtmb.2016.0115",
      "author": "AM Saldaña-Cruz",
      "doi-asserted-by": "publisher",
      "first-page": "702",
      "issue": "11",
      "journal-title": "Genet Test Mol Biomarkers",
      "key": "461_CR23",
      "unstructured": "Saldaña-Cruz AM, León-Moreno LC, Sánchez-Corona J, Santiago DA, Mendoza-Carrera F, Castro-Martínez XH, et al. CYP2C9 and CYP2C19 Allele and haplotype distributions in four mestizo populations from Western Mexico: An interethnic comparative study. Genet Test Mol Biomarkers. 2016;20(11):702–9.",
      "volume": "20",
      "year": "2016"
    },
    {
      "DOI": "10.1371/journal.pone.0162866",
      "author": "C Mizzi",
      "doi-asserted-by": "publisher",
      "first-page": "e0162866",
      "issue": "9",
      "journal-title": "PLoS ONE",
      "key": "461_CR24",
      "unstructured": "Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, et al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS ONE. 2016;11(9):e0162866.",
      "volume": "11",
      "year": "2016"
    },
    {
      "DOI": "10.1097/FPC.0b013e328333f70b",
      "author": "BG Nordestgaard",
      "doi-asserted-by": "publisher",
      "first-page": "77",
      "issue": "2",
      "journal-title": "Pharmacogenet Genomics",
      "key": "461_CR25",
      "unstructured": "Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics. 2010;20(2):77–85.",
      "volume": "20",
      "year": "2010"
    },
    {
      "DOI": "10.1038/s41397-021-00262-4",
      "author": "A Jaya Shankar",
      "doi-asserted-by": "publisher",
      "first-page": "100",
      "issue": "2",
      "journal-title": "Pharmacogenomics J",
      "key": "461_CR26",
      "unstructured": "Jaya Shankar A, Jadhao S, Hoy W, Foote SJ, Patel HR, Scaria V, et al. Pharmacogenomic analysis of a genetically distinct Indigenous population. Pharmacogenomics J. 2022;22(2):100–8.",
      "volume": "22",
      "year": "2022"
    },
    {
      "DOI": "10.1016/bs.apha.2018.02.001",
      "author": "G Suarez-Kurtz",
      "doi-asserted-by": "publisher",
      "first-page": "133",
      "journal-title": "Adv Pharmacol",
      "key": "461_CR27",
      "unstructured": "Suarez-Kurtz G, Parra EJ. Population diversity in pharmacogenetics: a latin American perspective. Adv Pharmacol. 2018;83:133–54.",
      "volume": "83",
      "year": "2018"
    },
    {
      "DOI": "10.3389/fphar.2010.00118",
      "author": "G Suarez-Kurtz",
      "doi-asserted-by": "publisher",
      "first-page": "118",
      "journal-title": "Front Pharmacol",
      "key": "461_CR28",
      "unstructured": "Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front Pharmacol. 2010;1:118.",
      "volume": "1",
      "year": "2010"
    },
    {
      "DOI": "10.1038/s41598-021-96590-3",
      "author": "F Fekete",
      "doi-asserted-by": "publisher",
      "first-page": "17081",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "461_CR29",
      "unstructured": "Fekete F, Mangó K, Déri M, Incze E, Minus A, Monostory K. Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. Sci Rep. 2021;11(1):17081.",
      "volume": "11",
      "year": "2021"
    },
    {
      "DOI": "10.1007/s13318-013-0124-2",
      "author": "E Varshney",
      "doi-asserted-by": "publisher",
      "first-page": "275",
      "issue": "4",
      "journal-title": "Eur J Drug Metab Pharmacokinet",
      "key": "461_CR30",
      "unstructured": "Varshney E, Saha N, Tandon M, Shrivastava V, Ali S. Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region. Eur J Drug Metab Pharmacokinet. 2013;38(4):275–82.",
      "volume": "38",
      "year": "2013"
    },
    {
      "DOI": "10.1097/FPC.0b013e328344c340",
      "author": "C Ciccacci",
      "doi-asserted-by": "publisher",
      "first-page": "344",
      "issue": "6",
      "journal-title": "Pharmacogenet Genomics",
      "key": "461_CR31",
      "unstructured": "Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, et al. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet Genomics. 2011;21(6):344–6.",
      "volume": "21",
      "year": "2011"
    },
    {
      "DOI": "10.2217/14622416.8.11.1545",
      "author": "P Borgiani",
      "doi-asserted-by": "publisher",
      "first-page": "1545",
      "issue": "11",
      "journal-title": "Pharmacogenomics",
      "key": "461_CR32",
      "unstructured": "Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics. 2007;8(11):1545–50.",
      "volume": "8",
      "year": "2007"
    },
    {
      "DOI": "10.1016/S0140-6736(98)04474-2",
      "author": "GP Aithal",
      "doi-asserted-by": "publisher",
      "first-page": "717",
      "issue": "9154",
      "journal-title": "Lancet",
      "key": "461_CR33",
      "unstructured": "Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717–9.",
      "volume": "353",
      "year": "1999"
    },
    {
      "DOI": "10.1056/NEJMoa1311386",
      "author": "M Pirmohamed",
      "doi-asserted-by": "publisher",
      "first-page": "2294",
      "issue": "24",
      "journal-title": "N Engl J Med",
      "key": "461_CR34",
      "unstructured": "Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.",
      "volume": "369",
      "year": "2013"
    },
    {
      "DOI": "10.1016/S0140-6736(14)61994-2",
      "author": "JL Mega",
      "doi-asserted-by": "publisher",
      "first-page": "2280",
      "issue": "9984",
      "journal-title": "Lancet",
      "key": "461_CR35",
      "unstructured": "Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2280–7.",
      "volume": "385",
      "year": "2015"
    },
    {
      "DOI": "10.1002/cpt.668",
      "author": "JA Johnson",
      "doi-asserted-by": "publisher",
      "first-page": "397",
      "issue": "3",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR36",
      "unstructured": "Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical pharmacogenetics implementation consortium (CPIC) Guideline for pharmacogenetics-Guided Warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404.",
      "volume": "102",
      "year": "2017"
    },
    {
      "DOI": "10.1517/17425255.2015.1053463",
      "author": "V Franco",
      "doi-asserted-by": "publisher",
      "first-page": "1269",
      "issue": "8",
      "journal-title": "Expert Opin Drug Metab Toxicol",
      "key": "461_CR37",
      "unstructured": "Franco V, Perucca E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab Toxicol. 2015;11(8):1269–79.",
      "volume": "11",
      "year": "2015"
    },
    {
      "DOI": "10.1002/cpt.2008",
      "author": "JH Karnes",
      "doi-asserted-by": "publisher",
      "first-page": "302",
      "issue": "2",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR38",
      "unstructured": "Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109(2):302–9.",
      "volume": "109",
      "year": "2021"
    },
    {
      "DOI": "10.1097/FPC.0000000000000186",
      "author": "A Figueiras",
      "doi-asserted-by": "publisher",
      "first-page": "66",
      "issue": "2",
      "journal-title": "Pharmacogenet Genomics",
      "key": "461_CR39",
      "unstructured": "Figueiras A, Estany-Gestal A, Aguirre C, Ruiz B, Vidal X, Carvajal A, et al. CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study. Pharmacogenet Genomics. 2016;26(2):66–73.",
      "volume": "26",
      "year": "2016"
    },
    {
      "DOI": "10.1002/cpt.794",
      "author": "T Grosser",
      "doi-asserted-by": "publisher",
      "first-page": "611",
      "issue": "4",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR40",
      "unstructured": "Grosser T, Theken KN, FitzGerald GA. Cyclooxygenase inhibition: pain, inflammation, and the cardiovascular system. Clin Pharmacol Ther. 2017;102(4):611–22.",
      "volume": "102",
      "year": "2017"
    },
    {
      "DOI": "10.1016/S0140-6736(13)60900-9",
      "author": "N Bhala",
      "doi-asserted-by": "publisher",
      "first-page": "769",
      "issue": "9894",
      "journal-title": "Lancet",
      "key": "461_CR41",
      "unstructured": "Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.",
      "volume": "382",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.clpt.2005.11.007",
      "author": "MS Lundblad",
      "doi-asserted-by": "publisher",
      "first-page": "287",
      "issue": "3",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR42",
      "unstructured": "Lundblad MS, Ohlsson S, Johansson P, Lafolie P, Eliasson E. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clin Pharmacol Ther. 2006;79(3):287–8.",
      "volume": "79",
      "year": "2006"
    },
    {
      "DOI": "10.1002/cpt.1830",
      "author": "KN Theken",
      "doi-asserted-by": "publisher",
      "first-page": "191",
      "issue": "2",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR43",
      "unstructured": "Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191–200.",
      "volume": "108",
      "year": "2020"
    },
    {
      "DOI": "10.1038/clpt.2013.190",
      "author": "J Pink",
      "doi-asserted-by": "publisher",
      "first-page": "199",
      "issue": "2",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR44",
      "unstructured": "Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther. 2014;95(2):199–207.",
      "volume": "95",
      "year": "2014"
    },
    {
      "DOI": "10.1097/FPC.0000000000000014",
      "author": "JH You",
      "doi-asserted-by": "publisher",
      "first-page": "6",
      "issue": "1",
      "journal-title": "Pharmacogenet Genomics",
      "key": "461_CR45",
      "unstructured": "You JH. Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. Pharmacogenet Genomics. 2014;24(1):6–14.",
      "volume": "24",
      "year": "2014"
    },
    {
      "DOI": "10.1002/cpt.1944",
      "author": "Y Zhou",
      "doi-asserted-by": "publisher",
      "first-page": "160",
      "issue": "1",
      "journal-title": "Clin Pharmacol Ther",
      "key": "461_CR46",
      "unstructured": "Zhou Y, Krebs K, Milani L, Lauschke VM. Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing. Clin Pharmacol Ther. 2021;109(1):160–74.",
      "volume": "109",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41586-020-2308-7",
      "author": "KJ Karczewski",
      "doi-asserted-by": "publisher",
      "first-page": "434",
      "issue": "7809",
      "journal-title": "Nature",
      "key": "461_CR47",
      "unstructured": "Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–43.",
      "volume": "581",
      "year": "2020"
    },
    {
      "DOI": "10.1038/nature15393",
      "author": "A Auton",
      "doi-asserted-by": "publisher",
      "first-page": "68",
      "issue": "7571",
      "journal-title": "Nature",
      "key": "461_CR48",
      "unstructured": "Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.",
      "volume": "526",
      "year": "2015"
    }
  ],
  "reference-count": 48,
  "references-count": 48,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00461-z"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "17"
}